Skopos Labs, Inc. Supernus Pharmaceuticals, Inc. Transaction History
Skopos Labs, Inc.
- $330 Million
- Q4 2024
A detailed history of Skopos Labs, Inc. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Skopos Labs, Inc. holds 35 shares of SUPN stock, worth $1,107. This represents 0.0% of its overall portfolio holdings.
Number of Shares
35Holding current value
$1,107% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SUPN
# of Institutions
303Shares Held
60.7MCall Options Held
22.3KPut Options Held
6K-
Black Rock Inc. New York, NY10.4MShares$329 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.15MShares$195 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.84MShares$153 Million2.47% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$91.1 Million0.03% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$83.2 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.69B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...